# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Date of Report: April 24, 2009 (Date of earliest event reported)

## Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL (State or other jurisdiction of incorporation) 001-38122 (Commission File Number) 59-3410522 (IRS Employer Identification Number)

13700 Progress Blvd (Address of principal executive offices)

32615 (Zip Code)

386-418-4018 (Registrant's telephone number, including area code)

Not Applicable (Former Name or Former Address, if changed since last report)

eck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; APPOINTMENT OF CERTAIN OFFICER; COMPENSATORY ARRANGEMENT OF CERTAIN OFFICER

(b) Effective April 24, 2009 Mr. Robert Zaharadnik resigned as Acting Chief Operating Officer of the Company.

#### **SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 29th day of April, 2009.

**ORAGENICS, INC.** (Registrant)

By: /s/ David Hirsch

David Hirsch Chief Financial Officer